BUTALAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Butalan, and when can generic versions of Butalan launch?
Butalan is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in BUTALAN is butabarbital sodium. There are nine drug master file entries for this compound. Additional details are available on the butabarbital sodium profile page.
Summary for BUTALAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 10 |
| Patent Applications: | 296 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | BUTALAN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for BUTALAN
US Patents and Regulatory Information for BUTALAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | BUTALAN | butabarbital sodium | ELIXIR;ORAL | 085880-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
